The US FDA has approved oral semaglutide (Rybelsus) for reducing the risk of major cardiovascular events in adults with type 2 diabetes at high heart-disease risk. The drug lowers chances of heart attack and stroke even in patients without prior cardiovascular events. It's the first oral GLP-1 receptor agonist cleared for heart protection in diabetics.